by Devendra Kumar Singh Varshney, PhD; Manju Agrawal, PhD; Rakesh Kumar Tripathi, PhD, MPhil; and Satish Rasaily, MD Dr. Varshney is with DCV Institute of Indology in Lucknow, India. Dr.
by Charles D. Cash, JD, LLM Mr. Cash is Associate Director of Risk Management at Professional Risk Management Services (PRMS). FUNDING: No funding was provided for the preparation of this
Innov Clin Neurosci. 2025;22(1–3):11–13. Dear Editor: I read with interest Lawrence’s article about a 33-year-old male patient with migraine with aura who self-experimented with psilocybin for his migraine attacks, which
Innov Clin Neurosci. 2025;22(1–3):11–13. Dear Editor: Thank you for your interest in this case report1 and for your insightful comments. I appreciate the thoroughness of your feedback and concur with
Innov Clin Neurosci. 2025;22(1–3):11–13. Dear Editor: Emerging data on sex differences in the efficacy and tolerability of antipsychotics in patients with schizophrenia are not taken into account in current guidelines,
